- Home
- OSBC vs ANAB Comparison
OSBC vs ANAB Comparison
Compare OSBC & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OSBC
- ANAB
- Stock Information
- Founded
- OSBC 1981
- ANAB 2005
- Country
- OSBC United States
- ANAB United States
- Employees
- OSBC N/A
- ANAB N/A
- Industry
- OSBC Major Banks
- ANAB Biotechnology: Pharmaceutical Preparations
- Sector
- OSBC Finance
- ANAB Health Care
- Exchange
- OSBC Nasdaq
- ANAB Nasdaq
- Market Cap
- OSBC 770.5M
- ANAB 621.1M
- IPO Year
- OSBC N/A
- ANAB 2017
- Fundamental
- Price
- OSBC $18.24
- ANAB $22.50
- Analyst Decision
- OSBC Buy
- ANAB Buy
- Analyst Count
- OSBC 5
- ANAB 10
- Target Price
- OSBC $20.00
- ANAB $44.25
- AVG Volume (30 Days)
- OSBC 209.3K
- ANAB 659.2K
- Earning Date
- OSBC 07-16-2025
- ANAB 08-04-2025
- Dividend Yield
- OSBC 1.35%
- ANAB N/A
- EPS Growth
- OSBC N/A
- ANAB N/A
- EPS
- OSBC 1.83
- ANAB N/A
- Revenue
- OSBC $275,720,000.00
- ANAB $111,872,000.00
- Revenue This Year
- OSBC $21.45
- ANAB N/A
- Revenue Next Year
- OSBC $12.41
- ANAB $24.39
- P/E Ratio
- OSBC $9.69
- ANAB N/A
- Revenue Growth
- OSBC 2.88
- ANAB 387.20
- 52 Week Low
- OSBC $14.14
- ANAB $12.21
- 52 Week High
- OSBC $19.46
- ANAB $41.31
- Technical
- Relative Strength Index (RSI)
- OSBC 67.80
- ANAB 45.71
- Support Level
- OSBC $17.09
- ANAB $22.49
- Resistance Level
- OSBC $17.86
- ANAB $24.86
- Average True Range (ATR)
- OSBC 0.38
- ANAB 1.15
- MACD
- OSBC 0.09
- ANAB -0.27
- Stochastic Oscillator
- OSBC 96.18
- ANAB 0.00
About OSBC Old Second Bancorp Inc.
Old Second Bancorp Inc is a bank holding company. It provides consumer and commercial banking products such as demand, money market, savings, time deposit, and individual retirement as well as commercial, industrial, consumer, and real estate lending, including installment loans, student loans, agricultural loans, lines of credit and overdraft checking, safe deposit operations, trust services, wealth management services, and additional services tailored to the needs of individual customers, corporates, small-medium enterprises. The Company has one operating segment, which is community banking. The company's revenue consists of interest, commission, payments, and other income.
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).